Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Journal ArticleDOI
Omalizumab in asthma: is the therapeutic window too small?
K. Deepa Bhat,William J. Calhoun +1 more
TL;DR: This report reemphasizes the folly of using 80% predicted as a threshold to separate normal from abnormal for other pulmonary function parameters and improves the reporting of data from pulmonary function laboratories.
Drug Class Review: Controller Medications for Asthma
Daniel E Jonas,Roberta Wines,Marcy DelMonte,Halle R Amick,Tania M Wilkins,Brett D. Einerson,Christine L Schuler,Blake A Wynia,Betsy Bryant Shilliday +8 more
TL;DR: The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes.
GINA Workshop Report (Updated 2004) Global Strategy for Asthma Management and Prevention
E.D. Bateman,Jean Bousquet,William W Busse,Pierluigi Paggiaro,Peter J. Barnes,Jeffrey M. Drazen,Mark FitzGerald,Peter G. Gibson +7 more
Journal ArticleDOI
Improvement of asthma control with omalizumab in 2 obese pediatric asthma patients
Kenny Y.C. Kwong,Craig A. Jones +1 more
TL;DR: Patients with difficult-to-treat asthma may benefit from receiving omalizumab even if they fall outside current dosing guidelines because of high body weight, as reported in 2 obese pediatric patients with severe persistent asthma.
Journal ArticleDOI
Ethnic differences in adverse drug reactions to asthma medications: a systematic review
TL;DR: It is suggested that the inclusion of ADR analysis by different ethnic backgrounds is desirable, and despite the higher prevalence of asthma among specific ethnic minority groups, few studies disaggregated information by ethnic background, and reports of ADRs to asthma medications in different ethnic groups were rare.
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.